Selective brain dopamine (DA) depletions in rats, induced by neonatal intracisternal administration of 6-hydroxydopamine (6-OHDA; 75 μg), caused spontaneous hyperactivity at the adult stage as measured using determinations of locomotion, rearing and total activity. Treatment with ketanserin (0.5 or 1.0 mg/kg, s.c.) reversed the hyperactivity in 6-OHDA-treated animals during a 90-min period following injection, although only the low dose of ketanserin reduced rearings. In control animals ketanserin treatment did not affect the locomotion or total activity counts, while the high dose of ketanserin increased rearings. Following treatment with mianserin (0.5 or 1.0 mg/kg, s.c.), a similar effect was seen; however, it was longer-lasting and mianserin treatment increased activity in controls. Regional analysis of monoamine levels demonstrated a marked reduction of basal forebrain DA levels, while in striatum an increase in serotonin (5-HT) concentration was seen following the 6-OHDA treatment. The results indicate that drugs with a high affinity to 5-HT2 binding sites can influence the hyperactivity seen in neonatally DA-lesioned rats. This effect might be related to inhibition of 5-HT pathways directly involved in regulation of motor activity or due to alterations in the interaction between the DA and 5-HT systems as a consequence of the early DA lesion.
Get full access to this article
View all access options for this article.
References
1.
Blandina P., Goldfarb J., Green J.P. (1988) Activation of a 5-HT3 receptor releases dopamine from rat striatal slices. Eur J Pharmacol155: 349-350
2.
Breese G.R., Vogel R.A., Mueller R.A. (1978) Biochemical and behavior alterations in developing rats treated with 5,7-dihydroxytryptamine. J Pharmacol Exp Ther205: 587-595
3.
Bruno J.P., Jackson D., Zigmond M.J., Stricker E.M. (1987) Effects of dopamine-depleting brain lesions in rat pups: Role of striatal serotonergic neurons in behavior. Behav Neurosci101: 806-811
4.
Callaway C.W., Wing L.L., Geyer A.A. (1990) Serotonin release contributes to the locomotor stimulant effects of 3,4,-methylenedioxymethamphetamine in rats. J Pharmacol Exp Ther254: 456-464
5.
Costall B., Domeney A.M., Naylor R.J. (1990) 5-HT3 receptor antagonists attenuate dopamine-induced hyperactivity in the rat. NeuroReport1: 77-80
6.
Duncan G.E., Criswell H.E., McCown T.J., Paul I.A., Mueller R.A., Breese G.R. (1987) Behavioral and neurochemical responses to haloperidol and SCH-23390 in rats treated neonatally or as adults with 6-hydroxydopamine . Pharmacol Exp Ther243: 1027-1034
7.
Ennis C., Kemp J.D., Cox B. ( 1981) Characterization of inhibitory 5-hydroxytryptamine receptors that modulate dopamine release in the striatum. J Neurochem36: 1515-1520
8.
Erinoff L., MacPhail R.C., Heller A., Seiden L.S. (1979) Age-dependent effects of 6-hydroxydopamine on locomotor activity in the rat. Brain Res164: 195-205
9.
Glennon R.A., Slusher R.M., Lyon R A, Titeler M., McKenney JD (1986) 5-HT1 and 5-HT 2 binding characteristics of some quipazine analogues. J Med Chem29: 2375-2380
10.
Green A.R., Heal D.J. (1985) The effects of serotonin-mediated behavioural models . In Green A R (ed.), Neuropharmacology of serotonin. Oxford University Press , New York, pp. 326-355
11.
Guan X-M., McBride W.J. (1989) Serotonin microinfusion into the ventral tegmental area increases accumbens dopamine release. Brain Res Bull23: 541-547
12.
Heffner T.G., Seiden L.S. (1982) Possible involvement of serotonergic neurons in the reduction of locomotor hyperactivity caused by amphetamine in neonatal rats depleted of brain dopamine. Brain Res244: 81-90
13.
Herve D., Pickel V.M., Joh T.H., Beudet A. (1987) Serotonin axon terminals in the ventral tegmental area of the rat: fine structure and synaptic input to dopaminergic neurons . Brain Res435: 71-83
14.
Kirk R.E. (1968) Experimental design: procedures for the behavioral sciences. Brooks/Cole, Belmont CA
15.
Krulich L., McCann S.M., Mayfield M.A. (1981) On the mode of the prolactin release-inhibition action of the serotonin blockers metergolide, methysergide and cyproheptadine . Endocrinology108: 1115-1124
16.
Leysen J.E. (1985) Characterization of serotonin receptor binding sites. In Green A R (ed.), Neuropharmacology of serotonin. Oxford University Press , New York, pp. 79-109
17.
Leysen J.E., Wynants J., Eens A., Janssen P A J (1989) Ketanserin reduces a particular monoamine pool in peripheral tissues. Mol Pharmacol35: 375-380
18.
Lucot J.B., Seiden L.S. (1982) Effects of neonatal administration of 5,7-dihydroxytryptamine on locomotor activity. Psychopharmacology77: 114-116
19.
Luthman J., Bolioli B., Tsutsumi T., Verhofstad A., Jonsson G. (1987) Sprouting of striatal serotonin nerve terminals following selective lesions of nigro-striatal dopamine neurons in the neonatal rat. Brain Res Bull19: 269-274
20.
Luthman J., Fredriksson A., Jonsson G., Archer T. (1989a) Selective neonatal lesion of central dopamine and noradrenaline neuron systems in the neonatal rat: motor behavior and monoamine alterations at adult stage. Behav Brain Res33: 267-277
21.
Luthman J., Fredriksson A., Lewander T., Jonsson G., Archer T. (1989b) Effects of d-amphetamine and methylphenidate on hyperactivity produced by neonatal 6-hydroxydopamine treatment. Psychopharmacology99: 550-557
22.
Luthman J., Brodin E., Sundström E., Wiehager B. (1990a) Studies on brain monoamine and neuropeptide systems after neonatal intracerebroventricular 6-hydroxydopamine treatment. Int J Dev Neurosci8: 549-560
23.
Luthman J., Lindqvist E., Young D., Cowburn R. (1990b) Neonatal dopamine lesion in the rat results in enhanced adenylate cyclase activity without altering dopamine receptor binding or dopamine- and adenosine 3' :5'monophosphate-regulated phosphoprotein (DARPP-32) immunoreactivity. Exp Brain Res83: 85-95
24.
Muramatsu M., Tamaki-Ohashi J., Usuki C., Araki H., Chaki S., Aihara H. (1988) 5-HT2 antagonists and minaprine block the 5-HT-induced inhibition of dopamine release from the rat brain striatal slices. Eur J Pharmacol153: 89-95
25.
Nelson D.L. (1988) Biochemistry and pharmacology of the 5-HT 1 serotonin binding sites. In Sanders-Bush E (ed.), The serotonin receptors. Humana Press, Clifton, NJ, pp. 23-57
26.
Nicolaou N.M., Garcia-Munoz M., Arbuthnott G.W., Eccleston D. (1979) Interactions between serotonergic and dopaminergic system in the rat brain demonstrated by small lesions of the raphe nuclei . Eur J Pharmacol57: 295-305
27.
Ögren S-O., Fuxe K. ( 1985) Characterization of serotonin receptor binding sites. In Green A R (ed.), Oxford University Press, New York, pp. 131-180
28.
Papakostas Y., Markianos M., Stefanis C. (1988) Methysergide reduces the prolactin response to ECT. Biol Psychiatr24: 465-468
29.
Peroutka S.J. (1991) The molecular pharmacology of 5-hydroxytryptamine receptor subtypes. In Peroutka S J (ed.), Serotonin receptor subtypes: basic and clinical aspects. Wiley-Liss, New York, pp. 65-80
30.
Pierce P.A., Peroutka S.J. (1989) Evidence for distinct 5-hydroxytryptamine 2 binding site subtypes in cortical membrane preparations. J Neurochem52: 656-658
31.
Racagni G., Mocchetti I., Calderini G., Battistella A., Brunello N. (1983) Temporal sequence of changes in central noradrenergic system of rat after prolonged antidepressant treatment: receptor desensitization and neurotransmitter interactions. Neuropharmacology22: 415-424
32.
Shaywitz B.A., Klopper J.H., Yager R.D., Gordon J.W. (1976a) Paradoxical response to amphetamine in developing rats treated with 6-hydroxydopamine. Nature261: 153-155
33.
Shaywitz B.A., Yager R.D., Klopper J.H. (1976b) Selective brain dopamine depletion in developing rats: an experimental model of minimal brain dysfunction. Science191: 305-307
34.
Stachowiak M.K., Bruno J.P., Snyder A.M., Stricker E.M., Zigmond M.J. (1984) Apparent sprouting of striatal serotonergic terminals after dopamine-depleting brain lesions in neonatal rats. Brain Res291: 164-167
35.
Towle A.C., Criswell H.E., Maynard E.H., Lauder J.M., Joh T.H., Mueller R.A., Breese G.R. (1989) Serotonergic innervation of the caudate following a neonatal 6-hydroxydopamine lesion: An anatomical, biochemical and pharmacological study. Pharmacol Biochem Behav34: 367-374
36.
Ugedo L., Grenhoff J., Svensson T. (1989) Ritanserin, a 5-HT2 receptor antagonist, activates midbrain dopamine neurons by blocking serotonergic inhibition. Psychopharmacology98: 45-50
37.
Ungerstedt U. (1971) Adipsia and aphagia after 6-hydroxydopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand367: (Suppl) 95-122
38.
Wilkinson L.O., Dourish C.T. (1991) Serotonin and animal behavior. In Peroutka S J (ed.), Serotonin receptor subtypes: basic and clinical aspects. Wiley-Liss Inc., New York, pp.147-210
39.
Yagaloff K.A., Hartig P.R. (1985) 125I-Lysergic acid diethylamine binds to a novel serotonergic site on rat choroid plexus epithelial cells. J Neurosci5: 3178-3183
